Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients
Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients
复制标题
DOI：
10.1016/s1386-6532(99)00079-7
复制
发表时间：
2000-05-01
影响因子：
8.8
通讯作者：
Whitman, JE
中科院分区：
文献类型：
--
作者：
Ablashi, DV;Eastman, HB;Whitman, JE
背景：HHV-6是一种普遍存在的病毒，其感染多发生在儿童期，之后转为潜伏感染。HHV-6的再活化已被证明在AIDS和其他几种疾病的发病机制中起作用。目的：目的探讨HHV-6感染或再激活在多发性硬化（MS）和慢性疲劳综合征（CFS）发病机制中的作用。结果：21例MS和35例CFS患者进行了研究和临床随访。在这些患者中，我们测量了HHV-6 IgG和IgM抗体水平，并使用短期培养试验分析了其外周血单个核细胞（PBMC）中HHV-6的存在。在MS和CFS患者中，我们发现与健康对照组相比，HHV-6 IgM抗体水平较高，IgG抗体水平升高。70%的MS患者含有HHV-6晚期抗原（衣壳）的IgM抗体，而只有15%的健康供体（HD）和20%的其他神经系统疾病（OND）患者有HHV-6 IgM抗体。CFS患者IgM抗体检出率（57.1%）也高于HD患者（16%）。此外，54%的CFS患者表现出HHV-6早期蛋白（p41/38）抗体，而HD仅为8.0%。在MS和CFS患者中均检测到IgG抗体滴度升高。在短期培养试验中分析MS、CFS和HD的PBMC，以检测HHV-6抗原表达细胞，并将获得的病毒分离株表征为变体A或B。54%的MS患者含有HHV-6早期和晚期抗原产生细胞，87%的HHV-6分离株为变异体B。CFS患者的分离株主要为变异体A（70%），HD患者的分离株主要为变异体B（67%）。此外，来自OND的一个分离株也是变体B。在两名CFS患者中发现持续感染HHV-6超过2.5年，并在10名CFS患者的PBMC中检测到HHV-6特异性细胞免疫应答。结论：在MS和CFS患者中，我们发现HHV-6抗体和HHV-6 DNA水平升高。在CFS患者中也检测到细胞免疫应答的降低。这些数据表明，HHV-6再活化在这些疾病的发病机制中起作用。(C)2000 Elsevier Science B. V.保留所有权利。
Background: HHV-6 is a ubiquitous virus and its infection usually occurs in childhood and then becomes a latent infection. HHV-6 reactivation has been shown to play a role in the pathogenesis of AIDS and several other diseases. Objectives: To determine what role HHV-6 infection or reactivation plays in the pathogenesis of multiple sclerosis (MS) and chronic fatigue syndrome (CFS). Results: Twenty-one MS and 35 CFS patients were studied and followed clinically. In these patients, we measured HHV-6 IgG and IgM antibody levels and also analyzed their peripheral blood mononuclear cells (PBMCs) for the presence of HHV-6, using a short term culture assay. In both MS and CFS patients, we found higher levels of HHV-6 IgM antibody and elevated levels of IgG antibody when compared to healthy controls. Seventy percent of the MS patients studied contained IgM antibodies for HHV-6 late antigens (capsid), while only 15% of the healthy donors (HD) and 20% of the patients with other neurological disorders (OND) had HHV-6 IgM antibodies. Higher frequency of IgM antibody was also detected in CFS patients (57.1%) compared to HD (16%). Moreover, 54% of CFS patients exhibited antibody to HHV-6 early protein (p41/38) compared to only 8.0% of the HD. Elevated IgG antibody titers were detected in both the MS and the CFS patients. PBMCs from MS, CFS and HD were analyzed in a short term culture assay in order to detect HHV-6 antigen expressing cells and to characterize the viral isolates obtained as either Variant A or B. Fifty-four percent of MS patients contained HHV-6 early and late antigen producing cells and 87% of HHV-6 isolates were Variant B. Isolates from CFS, patients were predominately Variant A (70%) and isolates from HD were predominately Variant B (67%). Moreover, one isolate from OND was also Variant B. Persistent HHV-6 infection was found in two CFS patients over a period of 2.5 years and HHV-6 specific cellular immune responses were detected in PBMCs from ten CFS patients. Conclusions: In both MS and CFS patients, we found increased levels of HHV-6 antibody and HHV-6 DNA. A decrease in cellular immune responses was also detected in CFS patients. These data suggest that HHV-6 reactivation plays a role in the pathogenesis of these disorders. (C) 2000 Elsevier Science B.V. All rights reserved.